Mad Hedge Biotech and Healthcare Letter January 20, 2026 Fiat Lux Featured Trade: (FRONT-RUNNING FROM THE REAR) (GH)
Category Archives: Biotech Letter
Let’s be honest. No one wakes up thinking, “You know what would really make this week great? A colonoscopy.” Which is precisely why Guardant Health’s (GH) blood-based Shield test is one of the smartest plays in diagnostics right now. It lets people screen for colorectal cancer without, well… going there. It’s the rare biotech innovation […]
Mad Hedge Biotech and Healthcare Letter January 15, 2026 Fiat Lux Featured Trade: (PROGRESS LIKE CLOCKWORK) (GILD), (RHHBY), (JNJ), (ACLX)
Back in 2016, I told a hedge fund crowd in Tokyo that Gilead (GILD) was the biotech equivalent of a Seiko Spring Drive. Quietly brilliant, ruthlessly precise, engineered to perform for decades without needing applause. A few chuckled. Then Biktarvy happened. Now Yeztugo is here, and those same folks are calling me for dinner reservations […]
Mad Hedge Biotech and Healthcare Letter January 13, 2026 Fiat Lux Featured Trade: (NOT BAD FOR SCRAPS) (AZN), (PFE)
Everyone forgets that Pfizer (PFE) tried to buy AstraZeneca (AZN) for scraps back in 2014. The UK Parliament threw a fit, the deal died, and Wall Street moved on. Fast forward, AstraZeneca is worth double what Pfizer is. The press still treats it like a mid-tier pharma shop. Meanwhile, it’s running the table in oncology. […]
Mad Hedge Biotech and Healthcare Letter January 8, 2026 Fiat Lux Featured Trade: (YOU’LL WANT TO LEAVE BEFORE YOU SHOULD) (ABBV)
I remember landing in Tokyo years ago after a brutal trans-Pacific flight, the kind where your body shows up but your brain is still circling somewhere over the Aleutians. It was raining hard, my hotel in Shinjuku was wrapped in scaffolding, and the front desk politely explained that my room wouldn’t be ready for hours. […]
Mad Hedge Biotech and Healthcare Letter January 6, 2026 Fiat Lux Featured Trade: (TURNS OUT, THE CURE WAS THE EASY PART) (CRSP), (SANA), (BEAM), (NTLA), (PRME), (DTIL)
I met a young woman in Geneva last year. Mid-20s, poised, bright. She had sickle cell disease and told me her childhood had been a blur of hospital beds and missed school years. Then she mentioned something I didn’t expect. She was part of a Casgevy clinical trial. No crises in over two years. She […]